Cargando…

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) is an aminopeptidase that inhibits the enzymatic degradation of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptides, neuropeptides, and various chemokines. Recent studies reported that serum DPP-4 concentration is correlated with clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Yeon, Jang, Byoung Kuk, Song, Min Kyung, Kim, Hye Soon, Kim, Mi-Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484912/ https://www.ncbi.nlm.nih.gov/pubmed/31089516 http://dx.doi.org/10.7570/jomes.2017.26.3.188

Ejemplares similares

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)
por: Lee, Ji Yeon, et al.
Publicado: (2018)

Association between Serum Irisin Levels and Non-Alcoholic Fatty Liver Disease in Health Screen Examinees
por: Choi, Eun Sung, et al.
Publicado: (2014)

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188–96)
por: Koh, Gwanpyo
Publicado: (2018)

Dipeptidyl Peptidase 10, a Novel Prognostic Marker in Colorectal Cancer
por: Park, Heae Surng, et al.
Publicado: (2013)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis
por: Lee, Sahmin, et al.
Publicado: (2020)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease
por: Zhang, Yuanyuan, et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
por: Senmaru, Takafumi, et al.
Publicado: (2012)

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
por: Chae, Yu-Na, et al.
Publicado: (2015)

Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus
por: Inn, Kyung-Soo, et al.
Publicado: (2018)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2021)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells
por: Choi, Soon-Youn, et al.
Publicado: (2017)

Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway
por: Park, Dong-Seok, et al.
Publicado: (2018)

Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
por: Oh, Tae Jung, et al.
Publicado: (2013)

Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis
por: Liu, Xin, et al.
Publicado: (2016)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Obesity parameters, physical activity, and physical fitness are correlated with serum dipeptidyl peptidase IV activity in a healthy population
por: Sanz, B., et al.
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
por: Lamers, Daniela, et al.
Publicado: (2011)

Serum dipeptidyl peptidase-4 activity and progranulin level in polycystic ovary syndrome patients
por: Abolghasemi, Maryam, et al.
Publicado: (2022)

Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
por: Seo, Songyi, et al.
Publicado: (2020)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sg4gieg6f1kckmd82ffv1p37jv